medigraphic.com
ISSN 2221-2434 (Electronic)

2017, Number 1

<< Back Next >>

Finlay 2017; 7 (1)

Abdominal obesity, an anthropometric parameter predicting metabolic disorders

Castellanos GM, Benet RM, Morejón GAF, Colls CY

Language: Spanish
References: 35
Page: 81-90
PDF size: 269.01 Kb.


ABSTRACT

Background: Waist circumference perimeter, as an indirect indicator of abdominal obesity, is commonly presented as an essential element in the clinical assessment of obesity. The link between abdominal obesity and insulin resistance is proposed as the core of metabolic syndrome’s pathophysiology and complications.
Objective: To determine whether individuals with abdominal obesity present characteristics related to metabolic syndrome’s factors that differ from those observed in individuals with no abdominal obesity.
Methods: A comparative analytical study was performed including cases control and design in two different groups. The sample was composed of 98 individuals of both sexes randomly selected out of a universe of 510 workers population at the Medical University of Cienfuegos from September to December 2005. They were all tested as to blood pressure, cholesterol, HDL cholesterol, fasting glucose and triglycerides.
Results: Abdominal obesity was found in 30.6% of individuals. It was predominant in females (83.3%) older than 40 years. The number of cases of obesity linked to hypertension was similar to the number of cases with low HDL cholesterol (53.3%). Impaired glucose was found in 16.7% of cases.
Conclusions: Abdominal obesity is a health problem in the population included in this study and it increases as age does. Individuals with abdominal obesity are exposed to a higher risk of metabolic disorders, such as low levels of HDL cholesterol, high levels of triglycerides and total cholesterol, glucose alterations and hypertension.


REFERENCES

  1. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the Risk of Myocardial Infarction in 27,000 Participants from 52 Countries: A Case-Control Study. Lancet. 2005;366(9497):1640-49

  2. Calle EE, Thun MJ, Petrelli JM, Rodríguez C, Heath CW. Body- Mass Index and Mortality in a Prospective Cohort of U.S Adult. N England J Med. 1999;342:1097-1105

  3. Berdasco Gómez A, Romero del Sol JM, Jiménez Hernández JM. Circunferencia de la cintura en adultos de Ciudad de la Habana como indicador de riesgo de morbilidad. Revista Cubana AlimentNutr. 2002;16(1):48-53

  4. Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, et al. Comparison of the Associations of Body Mass Index and Measures of Central Adiposity and Fat Mass with Coronary Heart Disease, Diabetes, and All-cause: A Study Using Data From 4 UK Cohorts. Am J ClinNutr. 2010;91(3):547-56

  5. Reaven GM. Banting lecture 1988. Role of Insulin Resistance in Human Disease. Diabetes. 1988;37(12):1595-07

  6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97

  7. Alberti KG, Zimmet P, Shaw J, IDF; Epidemiology Task Force Consensus Group. The metabolic syndrome —a new worldwide definition. Lancet. 2005;366(9491):1059-62

  8. Despres JP. Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006;38(1):52-63

  9. Salvador J. The debate about metabolic syndrome: a cluster of concepts, perspectives, semantics and research. ObesMetab. 2007;3:1-4

  10. KimJ,MontagnaniM,KonKohK,QuonMJ. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888-904

  11. García Pérez R, García Moreno R. Prevalencia del síndrome metabólico y enfermedades clínicas asociadas en un grupo de población urbana del Centro de Salud Zona Centro de Badajoz. Semergen. 2007;33(9):449-55

  12. Antón García F, Mir Sánchez C, Lloréis Ortells G, Artieda Anivarro O, Soriano Benet P, Rodríguez Montes M. Síndrome metabólico en los pacientes diabéticos de un centro de salud. Semergen. 2007;33(6):282-6

  13. Palma Gámiz JL, Conget Donlo I, Bertomeu González V, Ascaso Gimilio JF, González Juanatey JR, Alegría Ezquerra E, et al. Prevalencia del síndrome metabólico en pacientes con enfermedad cardiovascular en España: estudio CLYDIA. Med Clin (Barc). 2007;128(11):407-13

  14. Shah T, Jonnalagadda SS, Kicklighter JR, Diwan S, Hopkins BL. Prevalence of metabolic syndrome risk factors among young adult Asian Indians. J Immigr Health. 2005;7(2):117-25

  15. Alegría Ezquerra E, Castellano Vázquez JM, Alegría Barrero A. Obesidad, síndromemetabólico y diabetes:implicacionescardiovascularesyactuació n terapéutica. Rev Esp Cardiol. 2008;61(7):752-64

  16. Shiwaku K, Nogi A, Kitajima K, Anuurad E, Enkhmaa B, Yamasaki M,et al. Prevalence of the Metabolic Syndrome using the Modified ATP III Definitions for Workers in Japan, Korea and Mongolia. J OccupHealth. 2005;47(2):126-35

  17. Benet Rodríguez M, Cabrera Núñez RM, Castillo Sardiñas P,PollCañizarezY, Suaréz Y. Prevalencia de síndrome metabólico en los trabajadores de la Facultad de Ciencias Médicas de Cienfuegos. Medisur [Revista en Internet]. 2005 [citado 13 May 2011];3(2):[aprox. 13p]. Disponible en: http://www.medisur.sld.cu/index.php/medisur/arti cle/view/104

  18. Lenfant C, Chobanian AV, Jones DW, Roccella EJ; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41(6):1178-9

  19. Regitz Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95(3):136-47

  20. Weinberg ME, Manson JE, Buring JE, Cook NR, Seely EW, Ridker PM, et al. Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women. Metabolism. 2006;55(11):1473-80

  21. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52(7):908-15

  22. Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J ObesRelatMetabDisord. 2000;24 Suppl 2:47-9

  23. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453-8

  24. Schmitz Peiffer C. Signalling aspects of insulin resistance in skeletal muscle. Mechanisms induced by lipid oversupply. Cell Signal. 2000;12(9-10):583-94

  25. Gómez Cía P. Alteraciones metabólicas y enfermedad cardiovascular. Hipertensión. 2004;21(7):331-3

  26. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007;120 Suppl 1:3-8

  27. Kaaja RJ, Poyhonen Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens. 2006;24(1):131-41

  28. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adiposetissue volumes are cross-sectionally related to markers ofinflammation and oxidative stress: the Framingham HeartStudy. Circulation. 2007;116(11):1234-41

  29. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752-61

  30. Mingrone G, Castagneto M. Role of lipids in insulin resistance and type 2 diabetes mellitus development. Nutrition. 1999;15(1):64-6

  31. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. AJPEndo. 2004;286(6):E891-5

  32. Amador N, Guizar JM, Malacara JM, Perez-Luque E, Paniagua R. Sympathetic activity and response to ACE inhibitor (enalapril) in normotensive obese and non-obese subjects. Arch Med Res. 2004;35(1):54-8

  33. Dolinkova M, Dostalova I, Lacinova Z, Michalsky D, Haluzikova D, Mraz M, et al. The endocrine profile of subcutaneousand visceral adipose tissue of obese patients. Mol Cell Endocrinol. 2008;291(1-2):63-70

  34. Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 2008;93(8):3215-21

  35. Kuk JL, Karzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an independent predictor of all-cause mortality in men. Obesity. 2006;14(2):336-41




2020     |     www.medigraphic.com